VBI Vaccines (OTCPK:VBIV.Q) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

VBIV.Q 주식 개요

상용 단계의 바이오 제약 회사인 VBI 백신은 면역 종양학 및 전염병 치료를 위한 백신을 개발 및 판매합니다.

VBIV.Q 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	0/6
과거 실적	0/6
재무 상태	2/6
배당금	0/6

보상

위험 분석

마이너스 주주 지분

최근 3개월간 주가 변동폭 심해

의미 있는 시가총액이 없습니다. ( $4M )

지난 5년간 매년 수익이 17.4% 씩 감소했습니다.

+ 1 더 많은 위험

VBI Vaccines Inc. 경쟁사

TRACON Pharmaceuticals

OTCPK:TCON

US$294.7k

IPI Legacy Liquidation Co

OTCPK:IMPL.Q

US$358.5k

Scorpius Holdings

NYSEAM:SCPX

US$14.2m

Bellerophon Therapeutics

OTCPK:BLPH

US$428.1k

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 VBI Vaccines
과거 주가
현재 주가	US$0.037
52주 최고치	US$1.35
52주 최저치	US$0.02
베타	2.17
11개월 변경	-95.11%
3개월 변경 사항	-94.07%
1년 변경 사항	-97.08%
33년 변화	-99.96%
5년 변화	-99.82%
IPO 이후 변화	-99.99%

최근 뉴스 및 업데이트

Recent updates

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Aug 26

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Jun 17

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Jun 09

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

Jan 24

주주 수익률

	VBIV.Q	US Biotechs	US 마켓
7D	-60.9%	-1.1%	0.1%
1Y	-97.1%	9.3%	17.5%

수익률 대 산업: VBIV 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: VBIV 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is VBIV.Q's price volatile compared to industry and market?
VBIV.Q volatility
VBIV.Q Average Weekly Movement	46.9%
Biotechs Industry Average Movement	10.6%
Market Average Movement	6.2%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

안정적인 주가: VBIV 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: VBIV 의 주간 변동성은 지난 1년 동안 16% 에서 23% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
n/a	135	Jeff Baxter	www.vbivaccines.com

상용 단계의 바이오 제약 회사인 VBI 백신은 면역 종양학 및 전염병 치료를 위한 백신을 개발 및 판매합니다. 프리헤브리오, 프리헤브리, Sci-B-Vac이라는 브랜드명으로 B형 간염(HBV) 백신을 제공합니다. 또한 만성 HBV 감염 치료를 위한 단백질 기반 면역치료 후보물질인 VBI-2601, 교모세포종 암 백신 면역치료 후보물질인 VBI-1901, 예방적 거대세포바이러스 백신 후보물질인 VBI-1501, 지카 바이러스 치료용 VBI-2501을 개발하고 있습니다.

VBI Vaccines Inc. 기본 사항 요약

VBI Vaccines 의 수익과 매출은 시가총액과 어떻게 비교하나요?
VBIV.Q 기본 통계
시가총액	US$808.84k
수익(TTM)	-US$83.99m
수익(TTM)	US$9.41m

0.1x

P/S 비율

0.0x

P/E 비율

VBIV.Q 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
VBIV.Q 손익 계산서(TTM)
수익	US$9.41m
수익 비용	US$11.67m
총 이익	-US$2.26m
기타 비용	US$81.73m
수익	-US$83.99m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-2.93
총 마진	-24.03%
순이익 마진	-892.47%
부채/자본 비율	-891.6%

VBIV.Q 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

VBIV.Q 주식 개요

보상

위험 분석

VBI Vaccines Inc. 경쟁사

OTCPK:TCON

US$294.7k

OTCPK:IMPL.Q

US$358.5k

NYSEAM:SCPX

US$14.2m

OTCPK:BLPH

US$428.1k

가격 내역 및 성능

최근 뉴스 및 업데이트

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

Recent updates

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Inc. announced delayed annual 10-K filing

VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Consensus revenue estimates increase by 291%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Consensus EPS estimates upgraded to US$4.46 loss

New major risk - Shareholder dilution

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

VBI Vaccines Inc. announced that it expects to receive $3 million in funding from Brii Biosciences Limited

VBI Vaccines Inc.(NasdaqCM:VBIV) dropped from Russell 2000 Dynamic Index

VBI Vaccines Inc. Announces Prehevbri® Is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Now 21% undervalued after recent price drop

Consensus revenue estimates decrease by 38%, EPS upgraded

Price target decreased by 45% to US$33.00

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 1,377%

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

VBI Vaccines Inc. Announces Health Canada Approval for Prehevbrio™ for Prevention of Hepatitis B in Adults

No longer forecast to breakeven

VBI Vaccines Presents Additional Phase 1/2A Data from VBI-1901 in Recurrent GBM At the 2022 Society for Neuro-Oncology Annual Meeting

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

VBI Vaccines Inc. Announces Presentation of Physician-Initiated Compassionate Use Data of Its 3-Antigen Hepatitis B Vaccine At the 2022 International HBV Meeting

VBI Vaccines gets up to $100M debt funding from K2 HealthVentures

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Consensus revenue estimates fall by 32%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Receives Non-Compliance Notice from Nasdaq

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for Its 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

VBI Vaccines Inc. Announces Updated Phase 2A Tumor Response and Overall Survival Data for VBI-1901

VBI Vaccines Inc. Announces UK MHRA Marketing Authorisation for Prehevbri

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Forecast to breakeven in 2024